Roivant Sciences (NASDAQ:ROIV – Get Free Report) had its target price hoisted by equities research analysts at Guggenheim from $46.00 to $48.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim‘s price objective suggests a potential upside of 19.78% from the company’s current price.
Several other research analysts have also commented on ROIV. Stifel Nicolaus began coverage on Roivant Sciences in a research report on Wednesday, September 16th. They issued a “buy” rating and a $51.00 price target for the company. UBS Group set a $55.00 price objective on Roivant Sciences in a research report on Wednesday, September 9th. HC Wainwright raised their price objective on Roivant Sciences from $47.00 to $48.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. Jefferies Financial Group raised their price objective on Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. Finally, TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.82.
View Our Latest Research Report on ROIV
Roivant Sciences Stock Up 1.4%
Roivant Sciences stock opened at $40.07 on Monday. The company’s 50-day moving average price is $37.31 and its 200-day moving average price is $32.25. The company has a market cap of $28.95 billion, a PE ratio of -62.83 and a beta of 1.23. Roivant Sciences has a twelve month low of $19.96 and a twelve month high of $42.50.
Insider Transactions at Roivant Sciences
In related news, CEO Eric Venker sold 187,943 shares of the company’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $40.53, for a total transaction of $7,617,329.79. Following the transaction, the chief executive officer directly owned 811,211 shares in the company, valued at approximately $32,878,381.83. This represents a 18.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa B. Epperly sold 17,750 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $36.10, for a total transaction of $640,775.00. Following the transaction, the director owned 14,954 shares in the company, valued at $539,839.40. The trade was a 54.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,982,747 shares of company stock worth $74,398,784. 8.80% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of ROIV. Wellington Management Group LLP grew its stake in shares of Roivant Sciences by 179.0% during the second quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock valued at $95,124,000 after buying an additional 1,724,588 shares during the last quarter. Maverick Capital Ltd. purchased a new stake in shares of Roivant Sciences in the first quarter worth approximately $45,066,000. Assenagon Asset Management S.A. lifted its stake in shares of Roivant Sciences by 18.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock worth $295,965,000 after acquiring an additional 1,286,464 shares during the last quarter. Affinity Asset Advisors LLC lifted its stake in shares of Roivant Sciences by 64.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company’s stock worth $77,560,000 after acquiring an additional 1,100,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. purchased a new position in Roivant Sciences during the 3rd quarter valued at $35,624,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.
Roivant Sciences Company Profile
Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.
Recommended Stories
- Five stocks we like better than Roivant Sciences
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
